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Abstract
Prion diseases, or transmissible spongiform encephalopathies (TSEs) are typically characterised by CNS accumulation of PrPSc, an aberrant
conformer of a normal cellular protein PrPC. It is thought PrPSc is itself infectious and the causative agent of such diseases. To date, no chemical
modifications of PrPSc, or a sub-population thereof, have been reported. In this study we have investigated whether chemical modification of
amino acids within PrP might cause this protein to exhibit aberrant properties and whether these properties can be propagated onto unmodified
prion protein. Of particular interest were post-translational modifications resulting from physiological conditions shown to be associated with TSE
disease. Here we report that in vitro exposure of recombinant PrP to conditions that imitate the end effects of oxidative/nitrative stress in TSE-
infected mouse brains cause the protein to adopt many of the physical characteristics of PrPSc. Most interestingly, these properties could be
propagated onto unmodified PrP protein when the modified protein was used as a template. These data suggest that post-translational
modifications of PrP might contribute to the initiation and/or propagation of prion protein-associated plaques in vivo during prion disease, thereby
high-lighting novel biochemical pathways as possible therapeutic targets for these conditions.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
The transmissible spongiform encephalopathies include
bovine spongiform encephalopathy (BSE) in cattle [1],
Creutzfeldt–Jakob disease (CJD) in humans [2] and scrapie in
sheep [3]. Also known as prion diseases, they are fatal
transmissible neurodegenerative conditions of the central
nervous system (CNS) which are characterised by the
accumulation of PrPSc [4] an abnormal isomer of the host
protein PrPC. It has been hypothesized that the transmissible
agent of these diseases consists solely of proteinaceous material
[5]. Consequently, it is proposed that PrPSc forms part, or all, of
the infectious prion agent and is responsible for the modification
of PrPC. The physical characteristics of PrPSc are profoundly
different to those of PrPC [5]. PrPSc occurs as an insoluble
aggregate which is often amyloid in character, with an increased
β-sheet secondary structure. It is partially resistant to proteinase
K treatment and can act as a template for the conversion of PrPC
to PrPSc.
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Attempts to validate the protein-only hypothesis have
focussed on converting recombinant protein into a form that
resembles PrPSc displaying both proteinase resistance and
infectivity. Early work produced proteinase K resistant recom-
binant PrP but there was no demonstrated infectivity [6].
However, more recent attempts have demonstrated evidence of
infectivity of an N-terminally truncated recombinant protein
refolded into a beta-sheet rich conformation [7,8] which
fibrillized readily. Other studies have produced oligomeric
forms of recombinant PrP, which possess other characteristics of
PrPSc but appear not to be infectious [9,10]. Within recent work,
there have been a few reports regarding the chemical modifica-
tions of prion protein each of which indicates varying degrees of
success in changing the protein's conformation [11–16].
Although the original studies on PrPSc maintain that there is
no difference in PrPC and PrPSc primary structure [17], studies
of PrPSc and infectivity titres have suggested that there may be
105 molecules of PrPSc per infectious unit with the possibility
that a sub-population of modified protein could be present.
Additionally, in long-lived post-mitotic cells such as neurons,
macromolecules can accumulate damage in the form of
modified amino-acids [18]. Such damage can manifest itself
as a progressive change in protein structure, charge and loss of
biochemical function. No comprehensive study exists regarding
any possible damage to prion protein and its possible
significance in the initial formation of PrPSc. Indeed, given
the extended incubation periods and late-stage onset associated
with TSE diseases, age-related modifications could realistically
have a role in disease progression.
Accordingly, we have been interested in determining to what
extent, if any, chemical modification of the prion protein might
cause the normal protein to exhibit any properties associated
with PrPSc. We were particularly interested in conditions that
might mimic altered physiological states that have been reported
to be associated with prion disease. Such a condition is
oxidative/nitrative stress, which has been reported to be present
in the brains of scrapie-infected mice [19,20]. More recently,
protein deposition in the form of disease-associated PrPSc has
been shown to correlate with the presence of oxidative stress in
TSE disease [21]. Oxidative stress can be defined as the
conditions under which oxidative free radicals are present in
excess of the cellular antioxidant defense mechanisms. This
causes a destructive condition since reactive oxygen and/or
nitrogen species, such as superoxide, peroxynitrite and hydroxyl
radicals, modify cellular components resulting in lipid perox-
idation, nitration and/or cross-linking of proteins and nucleic
acid mutations. This results in a fingerprint of characteristic
oxidative stress markers such as nitrotyrosine groups and/or
dityrosine cross-links being present in proteins of the target
tissue [22]. It is apparent that a number of neurodegenerative
diseases exhibit characteristic protein aggregation accompanied
by tyrosine nitration in the presence of oxidative stress reactants
which may include an oxidative enzyme [23,24]. For example,
rapid aggregation of α-synuclein, a protein identified in the
aggregates known as Lewy bodies associated with Parkinson's
disease, can be achieved in vitro by exposure to nitrative and
oxidative agents associated with oxidative stress [25].
Since oxidant-producing inflammatory enzyme systems
have been associated with other neurodegenerative diseases
[26], we decided to use such an oxidant system in this study to
achieve the post-translational modifications (PTMs) rather than
alternative methods of protein nitration and oxidation [27]. We
show that recombinant PrP protein exposed to an oxidant
environment exhibits many of the physical characteristics of
scrapie-associated prion protein and most importantly, the
modified PrP reveals an altered secondary structural content
similar to that reported for PrPSc [17]. In addition, we show that
many of these PrPSc-like properties can be templated onto
unmodified protein in vitro. This raises the possibility that such
modification of prion protein might have a role in the initiation
of PrPSc formation and contribute to the presence of prion
protein-associated plaques in vivo, thereby high-lighting
potential routes to novel targets for therapeutic reagents in the
future.
2. Methods
2.1. Ovine recombinant PrP
Oxidatively-refolded ovine recombinant PrP (amino acid residues 25–233,
with valine at residue 136, arginine at 154 and glutamine at 171; hereafter
referred to as rPrP) was provided by the Institute for Animal Health, Compton.
Protein was expressed in 1B392 E. coli and purified to homogeneity following
previously published methodology [28]. Electrospray mass spectrometry of rPrP
was used to confirm the correct amino acid sequence for this allelic variant of the
ovine prion protein and the presence of an internal disulphide bond. Circular
dichroism showed that the protein was predominately α-helical in structure.
2.2. Protein oxidation and nitration
Chemical modification of rPrP or lysozyme (Sigma, UK) was carried out by
incubation of the protein (600 μg/ml) with final concentrations of MNP reactants
viz. 0.006 U human myeloperoxidase (MPO) (Sigma, UK), 100 mM sodium
nitrite and 3% hydrogen peroxide (BDH, UK) at 37 °C with shaking for various
periods of time. Residual MPO activity was inhibited by the addition of sodium
azide to a final concentration of 25 mM and buffer exchange was carried out into
sodium acetate, pH 5.5 using centrifugal concentrators with a 10-kDa cut off
(Millipore, UK). For all subsequent investigations apart from mass spectro-
metry, chemical modification of rPrP or lysozyme (Sigma, UK) was carried out
as described previously. For mass spectrometry, concentrations of the reactants
were chosen which still allowed for modification of rPrP to be detected on
Western blot (see below and p. 11) viz. 0.3% H202 and 10 mMN02— but which
showed less propensity to aggregation. This was necessary for on-line HPLC-
mass spectrometry to be possible. On-line HPLC-mass spectrometry of
chemically modified proteins was carried out as described previously [14]. pH
was maintained at 5.5 throughout all procedures.
Chemical modification of rPrP was also carried out at four ten-fold dilutions
of the above reactants. This was to determine at which dilutions the protein was
modified. After incubation at 37 °C with shaking overnight, samples were
microfuged to separate aggregating protein as a pellet from that in the
supernatant. Pellets were re-dissolved in loading buffer (10 μl) or aliquots (5 μl)
of supernatant were mixed with loading buffer (5 μl). These samples were then
subjected to SDS-PAGE as described below.
2.3. Fourier-transform infra-red (FTIR) spectroscopy
Attenuated total reflection (ATR) Fourier transform infrared (FT-IR)
spectroscopy was used to determine the structural nature of the modified
protein. Spectra were recorded at room temperature on a Bruker Vector 22
infrared spectrometer equipped with a liquid nitrogen-cooled mercury cadmium
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telluride (MCT) detector at a nominal resolution of 4 cm−1. The spectrometer
was continuously purged with dried air to minimize the spectral contribution of
atmospheric water. Residual water vapour peaks were subtracted using reference
spectra. The internal reflection element was a germanium ATR plate
(50×20×2 mm) with an aperture angle of 45° yielding 25 internal reflections.
Thin films of hydrated PrP were obtained by depositing 30 μl of sample and
evaporating excess water under of N2 gas. To differentiate between α-helix and
random structures, prepared films were subjected to a stream of 2H2O-saturated
N2 gas for 30 min at room temperature. Peak fitting of the amide I band (1600–
1700 cm−1) was performed on non-deconvoluted spectra using GRAMS 32/AI
software (Thermogalactic, USA). Band assignments were made according to
Cabiaux et al. [29].
To investigate the structure of templated protein, FTIR spectra were recorded
at room temperature on a Bruker Equinox 55 spectrometer equipped with a
liquid nitrogen cooled mercury cadmium telluride detector. The sample
compartment was continuously purged with dry air. For each sample, 256
interferograms were collected at a spectral resolution of 2 cm−1. Sample and
buffer spectra were measured separately and subsequently subtracted using
Protein Dynamics software (Bruker). Thin films of hydrated rPrP were obtained
by depositing 200 μg of protein in a 30-μl volume on the crystal and subsequent
removal of excess water under a gentle N2 flow.
2.4. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
of modified rPrP
Oxidized/nitrated rPrP was reduced, carbamidomethylated and digested with
trypsin (1:100 enzyme:substrate ratio) overnight at 30 °C in 25 mM ammonium
bicarbonate at pH 8.5. The peptide products were analysed by on-line LC-MS/
MS. The tryptic peptides were separated on a reversed-phase column
(0.1×100 mm; Vydac C18) with a gradient of 0–30% (v/v) acetonitrile
(containing 0.1% (v/v) formic acid) over 30 min, at a flow rate of 500 nl/min.
Peptides were eluted via a nanoelectrospray interface into a quadrupole time-of-
flight mass spectrometer (Applied Biosystems). The mass spectral data were
matched to the protein sequence using Mascot software (Matrix Science) and
confirmed by manual interpretation of MS/MS spectra.
2.5. Amyloid formation in aggregated samples
The kinetics of aggregation of chemically modified rPrP samples was
monitored in 96-well plates by measurement of optical density (O.D.) at 490 nm
at 10 min intervals using a micro-plate reader (Opsys, Jencons, UK). Amyloid
formation was detected by one of two methods: aggregated samples were either
reacted with Congo Red, applied to glass slides and visualized in polarized light
using an Olympus BX41 microscope to show the presence of birefringence [30];
alternatively, addition of 25 μM Thioflavine T (ThT) solution prepared in
50 mM Tris–HCl, pH 8.0 was added to 1 μM modified or unmodified rPrP
protein in the wells of a 96-well plate and the mixture incubated for 25 °C for
5 min. Bound ThT was determined by fluorescence measurement (444 nm
excitation and 485 nm emission wavelength) at room temperature using a
fluorescence plate reader (Thermo Life Sciences, UK). Electron microscopy of
aggregated rPrP was performed by negative staining on carbon-coated,
600 mesh, copper grids. Samples were adsorbed to the grids for 30 s, stained
for 2 min with 2% (w/v) uranyl acetate and visualized at 100,000 magnification.
2.6. Measurement of proteinase K (PK) sensitivity
Prior to PK treatment, proteins were dialyzed against water using mini
dialysis units (Pierce, UK), according to the manufacturer's protocol. Protease
resistance was assessed by incubation of protein samples at 37 °C for 1 h with
PK (Sigma, UK) at 20 μg/ml. The reaction was stopped by the addition of the
protease inhibitor phenylmethylsulphonyl fluoride (PMSF) to a final concentra-
tion of 1 mM. Samples were analyzed by SDS-PAGE as described below.
2.7. SDS-PAGE and Western blot analysis of ovine rPrP
In general, protein samples were separated by SDS/PAGE under reducing
conditions using pre-cast 4–20% (w/v) tris-glycine gradient gels (Invitrogen,
Holland). Bands were visualized using the Coomassie®-based protein stain,
SimplyBlue™ (Sigma, UK) according to the manufacturer's protocol. Gels were
destained overnight, and then dried at 80 °C for 1 h for storage. The gels
displayed in this work are representative of at least 2 experiments. For Western
blotting, gels were blotted overnight onto Immobilin-P (Millipore, UK) transfer
membranes. Membranes were blocked for 30 min with TBS-T (10 mM Tris/
HCl, pH 7.8; 100 mM NaCl and 0.05% Tween 20) containing 5% (w/v) non-fat
milk and then incubated with rabbit polyclonal anti-nitrotyrosine (NT) antibody
(Cell Signalling Technology, Massachusetts, USA) at 20 °C for 2 h. Binding was
detected using biotinylated goat anti-rabbit IgG and visualized using an avidin–
peroxidase complex with diaminobenzidine as the substrate (Vector Labora-
tories, Peterborough, UK). Gel densitometry was carried out using the Scion
Image 1.63 software available at http://www.ScionCorp.com.
2.8. Templating procedure
In general, modified rPrP prepared as described above, was mixed at a
concentration ratio of approximately 1:100 (modified:unmodified protein) and
incubated for 24 h at room temperature with shaking. To ensure that incubated
unmodified protein could be distinguished from the modified template, the latter
was prepared using concentrations of NO2
−/H2O2 which had been shown by
western blot to cause a level of modifications which caused all the modified
protein to be pelletted on centrifugation (see Results section below). This was
confirmed by analysis of the supernatant by western blot which showed no
evidence of protein being present or was below the level of detection of our
western blot. After removal of the template samples of the unmodified rPrP
remaining in the supernatant were analyzed for PK resistance. This was done by
SDS-PAGE analysis followed by Coomassie blue staining and gel densitometry,
as described in Methods above.
2.9. Production of radio-labelled rPrP and templating procedure
Radio-labelled rPrP was produced by in vitro transcription/translation as
described previously [31]. 35S-labelled translation products were incubated
overnight at 37 °C with unlabelled oxidized/nitrated rPrP with shaking. After
digestion with PK at 20 μg/ml for 1 h at 37 °C, digests were analyzed by
SDS-PAGE.
3. Results
3.1. Characterisation of NO2
−/H2O2 modified rPrP
On exposure of rPrP to a series of dilutions of the MNP
(myeloperoxidase, nitrite and peroxide) system, it was found
that at high concentrations of nitrite and peroxide, the solution
turned yellow and a yellow precipitate was formed. The
precipitate was found to be insoluble even in concentrated
formic acid. The yellow coloration(λmax ∼410 nm, pH 8) was
attributed to the presence of nitrotyrosine residues [32,33,25].
Peptidyl nitrotyrosine has been shown previously to produce a
yellow coloration (λmax ∼428 nm, pH 8) [34,35]. Preliminary
experiments were therefore carried out to determine the
optimum concentrations of NO2
−/H2O2 that would allow some
of the modified protein to remain soluble for subsequent
analysis by mass spectrometric methods which tend to require
soluble analytes.
Consequently, soluble and pelleted fractions of modified
samples were analysed by SDS-PAGE and western blot for the
presence of nitrotyrosine. Experiments were carried out to
determine the optimum dose range of NO2
−/H2O2 to be used for
the modification of rPrP by exposing samples to a dose range
of four ten-fold dilutions of the reactants starting at 100 mM
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NO2
−/3% H2O2. Soluble and pelleted fractions were analysed
by western blot for the presence of nitrotyrosine. At a
concentration of 100 mMNO2
−/3% H2O2, nitrotyrosine residues
were most abundant in the pelleted fraction of modified rPrP
with very little present in the supernatant fraction (Fig. 1). At
10 mMNO2
−/0.3% H2O2, nitrotyrosine was detected in both the
pellet and supernatant fractions. At concentrations tested below
these ranges viz. 0.1 mM and 1 mM nitrite or 0.03 and 0.003%
peroxide, most nitrotyrosine was observed in the supernatant
fraction when reactants had been diluted a hundred fold. No
nitrotyrosines were detected at the lowest concentrations of
reactants used. Routinely, concentrations of NO2
− in the
millimolar range were used to modify rPrP.
In order to identify the nature and extent of amino acid
modification following exposure to NO2
−/H2O2, modified rPrP
protein was digested with trypsin and the resultant digest was
analyzed by LC-MS/MS. Peptides were identified that covered
58% of the sequence and included 10 out of the possible 14
tyrosine residues present in rPrP. The nature and extent of
oxidation of specific amino acid residues in rPrP was assessed
by difference in molecular mass compared to unmodified
residues (Table 1). Cysteine residues are known to be
susceptible to oxidation [36] and the cysteine at 217 was
completely oxidized to cysteic acid whilst methionine residues
were oxidized to sulphoxide and sulphone forms. No data were
acquired regarding the cysteine at 182. These oxidations
occurred at residues Met132, 137, 157, 209 and 216, and
Cys217. The tryptophan residues in the flexible N-terminal
region of the protein were also exposed to the oxidative
conditions, as amino acid Trp34 and Trp60 converted to the
dioxide form. Nitration was confirmed by a mass increase of
peptide fragments of 45 Da per modified residue. The highest
degree of tyrosine nitration was seen at residues Tyr41 and
Tyr52 (60% and 65% modified, respectively). The helix-1
epitope (DY148EDRY152Y153REN) has previously implicated
as being susceptible to oxidative modification [37]. Of the
tyrosine residues in this region of our modified rPrP, Tyr153
was the most nitrated at ∼37%, whilst Tyr148 and Tyr152 were
nitrated to a similar extent at approximately 22%.
The C-terminal proximal residues Tyr227 and Tyr228
were also nitrated, but less extensively than those within the
N-terminal region. This difference may presumably reflect the
fact that the C-terminal residues Tyr227 and Tyr228 are located
in the highly structured helix-3 in comparison to those within
the unstructured N-terminal region of the protein, which are
potentially more solvent exposed and more accessible to
modification.
3.2. Biophysical characterisation of modified rPrP aggregates
Preparations of aggregates of modified rPrP were investi-
gated by electron microscopy in order to determine their
biophysical characteristics. The majority (N95%) of the
modified protein showed larger amorphous structures, some
with diameters of up to 50 nm (Fig. 2a). There was also
evidence of a fine lattice arrangement of intertwined fibrillar-
type material with a diameter of approximately 10 nm (Fig. 2b).
Other techniques were also used to examine the nature of the
aggregated modified rPrP. Congo red staining showed evidence
of some birefringent material indicating the presence of fibrillar
structures but this was not confirmed by ThT staining as the
amount of fibrillar protein may have been below the sensitivity
of the test (data not shown).
FT-IR spectroscopy was used to compare the secondary
structure composition of unmodified and modified rPrP protein.
Fig. 1. Dose response of rPrP to NO2
−/H2O2. Recombinant prion protein samples
were treated with various concentrations of NO2
−/H2O2 as indicated in Methods.
After centrifugation, the pellets were re-dissolved in loading buffer. Equal
proportions of the re-dissolved pellets and equal proportions of the supernatants
were subjected to SDS-PAGE (see Methods). The modified protein runs as a
smear under these conditions, and nitrotyrosine reactivity was therefore
quantified by measuring the total optical density in each gel track. No
nitrotyrosine reactivity was observed in samples treated with the lowest
concentrations of reactants. As the reagent concentration is increased,
nitrotyrosine reactivity appears first in the supernatant (grey bars) and then
predominantly in the pellet (white bars). At the highest concentration of
reactants, nitrotyrosines were confined almost exclusively to the pellet.
Table 1
Mass spectrometric analysis of modified rPrP
Residues Modifications Ratio
Cys217 Unmodified:Cysteic acid 0:1
















Tyr227 and Tyr228 Unmodified:227-Nitrated:
228-Nitrated:both Nitrated
1:0.66:0.78:0.58
Relative amounts of the different modifications detected at each residue in
peptides obtained from modified rPrP. Residue numbering corresponds to native
ovine PrPC. Where two modified residues e.g. Met132 and Met137, Tyr41 and
Tyr52, or Tyr227 and Tyr228 occurred in the same peptide fragments and were
not resolved by reversed-phase liquid chromatography they were assessed
together.
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The modified rPrP protein was prepared as a precipitate under
conditions of high concentrations of NO2
−/H2O2 and in the
presence of MPO. The FT-IR spectrum of unmodified rPrP
contained an amide I band with a maximum absorption at
1652 cm−1 characteristic of proteins in a predominantly α-
helical conformation (Fig. 3). However, the spectrum of
modified rPrP possessed a broader amide I band with maxima
at 1648 cm−1 and 1621 cm−1, which is more characteristic of β-
sheet structure. Peak fitting analysis of the amide I band was
employed to quantify the main structural changes of rPrP upon
oxidation/nitration. Analysis of the unmodified rPrP amide I
band indicated that the protein had a secondary structural
content of 48.2% α-helix, 36.4% random coil, 12% β-turns and
3.4% β-sheet. This is in good agreement with NMR structures
of recombinant mammalian prion proteins [38,39]. In contrast,
modified rPrP had a secondary structure content of 34.7% α-
helix, 24% random coil, 15.1% β-turns and 25% β-sheet. This
indicated that the major structural change in modified rPrP was
an increase in β-sheet and a concomitant decrease in α-helix
content, in line with the PrPC to PrPSc transition.
3.3. Aggregate formation of modified rPrP
Exposure of rPrP to NO2
−/H2O2 in the presence of MPO
resulted in the formation of a yellow precipitate and therefore
allowed aggregate formation to be monitored by measuring the
turbidity of the reaction mix at 490 nm (Fig. 4a). Turbidity
measurements were performed at different concentrations of
rPrP to assess the kinetics of oxidation/nitration-induced
aggregation of the modified protein (Fig. 4b). The rate of the
aggregation reaction was calculated from the gradient of the
linear regression of these samples over 0–45 min, and plotted
against the respective PrP concentration (Fig. 4c). The increase
in optical density was linear over the time monitored and the
rate of the reaction was constant over the range measured and
the rate of aggregate formation increased linearly with rPrP
protein concentration. This confirmed that the reaction rate was
first order.
3.4. Modified rPrP displays protease resistance
A characteristic of PrPSc is its resistance to proteolysis.
Accordingly, we investigated whether NO2
−/H2O2 modified
rPrP, which had acquired some of the structural features of
disease-associated PrP had also acquired resistance to proteo-
lytic degradation. Proteolysis of rPrP by increasing concentra-
tion of PK was examined by SDS-PAGE and densitometry. Fig.
5a shows that mature length monomeric unmodified rPrP had a
molecular mass of 23 kDa and following treatment with PK at
10 μg/ml was readily digested into polypeptides of apparent
molecular mass of 12 and 13 kDa. When higher concentrations
of PK were used, smaller peptides of 9 and 5 kDa were
observed. Analysis of the profile of production of each of these
degradation products indicated that the 12- and 13-kDa
products were produced with similar kinetics and subsequently
degraded into the 9- and 5-kDa fragments. Most of the
unmodified rPrP protein was degraded at PK levels of
100 μg/ml (Fig. 5b). Conversely, modified rPrP was digested
in a similar manner to unmodified rPrP but resulted in only
a12 kDa fragment which persisted at high concentrations of PK
Fig. 3. FTIR spectroscopy of modified rPrP. FT-IR spectroscopic analysis
resulted in absorbance spectra for unmodified protein (black line) and modified
protein (dashed line). The latter showed a distinct shoulder at 1621 cm−1
characteristic of β-sheet structure which was absent in the unmodified protein
spectrum. Data shown are representative of three independent experiments.
Fig. 2. Electron microscopy of modified rPrP. (a) The majority of the modified
protein showed larger amorphous structures. (b) Example of a lattice work of
fibrillar-type material present in modified rPrP. Scale bars represent 100 nm.
796 D.V. Dear et al. / Biochimica et Biophysica Acta 1774 (2007) 792–802
(Fig. 5c and d). This suggested that modified rPrP had acquired
partial resistance to PK digestion.
3.5. Templating ability of modified rPrP
A striking feature of PrPSc is its apparent ability to transfer,
or template, its structural and PK-resistant properties onto PrPC
[40,41]. Accordingly, we investigated whether the NO2
−/H2O2
modified rPrP could induce structural changes and PK
resistance in unmodified rPrP. To ensure that unmodified
protein which had acquired PK resistance through templating
could be distinguished from the modified template, the latter
was prepared using concentrations of NO2
−/H2O2 which had
been shown previously by western blot to cause a level of
modifications which caused all the protein to be pelletted on
centrifugation. Samples of modified rPrP were mixed with
unmodified rPrP and, subsequently, modified rPrP was removed
from the reaction by centrifugation. The structure of templated,
unmodified rPrP remaining in the supernatant was assessed by
FTIR spectroscopy and compared to the starting, unmodified
rPrP. Fig. 6 shows the FT-IR spectrum of unmodified
untemplated rPrP, which was characterised by a broad amide I
band that lacked any well-resolved secondary structural bands.
In contrast, the unmodified templated rPrP is characterised by a
maximum at ∼1653 cm−1 within the amide I band, in addition
to a shoulder at ∼1620 cm−1 typical of β-sheet structures.
We also investigated whether the NO2
−/H2O2 modified rPrP
could induce PK resistance in unmodified rPrP. After 24 h
incubation, samples of templated rPrP were assessed for
acquisition of PK resistance (Fig. 7). Unmodified monomeric
rPrP was digested by 10 μg/ml PK with the concomitant
appearance of a protein band at 12 kDa, which was sub-
sequently cleaved upon digestion with increased concentration
of protease at both 0 and after 24 h incubation (Fig. 7a and c).
In contrast, whilst digestion of templated unmodified rPrP with
10 μg/ml PK led to a similar sized 12 kDa fragment at 0 h, after
24 h incubation with the modified template, this fragment was
resistant to digestion with up to 100 μg/ml of PK (Fig. 7b and
d). The PK resistance profile of templated unmodified rPrP was
similar to that seen by modified rPrP. In a further experiment to
assess PK resistance of templated rPrP, radiolabelled rPrP
translation products were incubated overnight at 37 °C in the
presence of unlabelled modified rPrP. After incubation, the
reaction mix was subjected to PK digestion followed by SDS-
PAGE and autoradiography. Fig. 8 shows that SDS-PAGE
analysis of radiolabelled unmodified PrP resulted in a band at
approximately 23 kDa representing a full-length translation
product(Fig. 8, lane 1), as described previously [31]. This
material was sensitive to digestion with 20 μg/ml PK (Fig. 8,
lane 2). However, when PK digestion was carried out on
radiolabelled unmodified translation products that had been
incubated with unlabelled modified rPrP, the templated
translation products acquired a PK-resistant core of 17–
20 kDa (Fig. 8, lanes 3 and 4). As can be seen, a substantial
fraction of the labelled protein was PK-resistant and is hence
not degraded, giving rise instead to a strong band of protein of
the size expected of the PK-resistant core. Each of these assays
Fig. 4. Aggregation assays of modified rPrP. (a) Aggregation of rPrP monitored
in the presence of different combinations of the MNP reactants (concentrations
as in Methods), as measured by turbidity at 490 nm. rPrP alone (open triangle)
or in the presence of MPO/H202 (closed diamond), MPO/NO2
− (filled circle),
NO2
−/H2O2 (filled square) and NO2
−/H2O2 /MPO (filled triangle). (b) Kinetics
of aggregation of rPrP modified in the presence of all MNP reactants (used at
ten-fold dilutions of concentrations in Methods) measured by turbidity analysis
of different concentrations of rPrP: Filled circle=1 mg/ml, filled square=
0.5 mg/ml, filled triangle=0.1 mg/ml, open circle=0.25 mg/ml, open
square=0.05 mg/ml and open triangle=−0 mg/ml. The data represents four
independent assays, and the error bars correspond to one standard deviation.
(c) The rate of the aggregation reaction was calculated as the gradient of the
linear regression of these samples over 0–45 min, and plotted against the
respective PrP concentration.
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would seem to indicate that both PK resistance and structure of
the modified protein had been propagated onto unmodified
rPrP.
4. Discussion
Two major pieces of evidence have supported the view that
the difference between PrPC and PrPSc resides in a change in
secondary structure since the primary sequences of the two PrP
isoforms are believed to remain identical and unmodified
[42,14]. However, the presence of a population of chemically
modified protein, whether minor or major, within the population
of disease-associated PrP molecules that might act as an
initiating template during PrPC to PrPSc conversion has never
been discounted [42]. It is important therefore, to establish
whether modifications of amino acid residues within PrP
protein may contribute to its conversion from PrPC to PrPSc
during disease pathogenesis. Identification of the biochemical
pathways responsible for such modifications of PrP during
prion diseases may prove to be suitable therapeutic targets for
inhibiting or retarding the progression of these as yet invariably
fatal conditions.
In our study reported here we have utilized the NO2
−/H2O2
system used previously in studies on alpha-synuclein [25] to
mimick oxidative stress-induced modification of rPrP. Mass
spectrometric analysis of NO2
−/H2O2 modified rPrP showed that
several tyrosine residues within the protein had been nitrated in
addition to oxidative modifications to other susceptible amino-
acids. Interestingly, when a dilution series of NO2
−/H2O2
reactants was tested, no nitration of rPrP amino acid residues,
or corresponding change of secondary structure, occurred at
concentrations of nitrite or peroxide lower than 10 mM as
determined by western blotting and CD spectroscopy (see
Fig. 5. Proteinase K resistance of modified rPrP. Unmodified (a and b) or modified (c and d) rPrP (1 mg/ml), was incubated with increasing concentrations of PK as
described in Methods, and the samples analysed by Coomassie staining after SDS-PAGE (a and c). Densitometric analysis of SDS-PAGE (b and d) recorded changes in
the level of protein species at 23 (filled square) and 12 kDa (filled diamond). (n=3 and Error bars depict one standard deviation). The 12-kDa fragment of modified
protein showed a greater degree of PK resistance at levels of PK between 40 and 100μg/ml, as compared to unmodified protein.
Fig. 6. Modified protein can propagate its structure onto unmodified protein.
FT-IR spectra of unmodified rPrP (continuous line) and unmodified rPrP after
it had been incubated with modified rPrP (dashed line), concentrations as in
Methods. A shoulder at around 1620 cm−1 is evident in the templated
unmodified protein indicative of the presence of β-sheet structures not present
in the spectrum of the unmodified and untemplated protein.
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previously). This is similar to studies reported by others which
have shown that it is only at high nitrite concentrations ( around
1 mM or above) that MPO catalyzes tyrosine nitration [43]. At
physiological levels of nitrite (0.5–210 μM) very little nitration
of tyrosine residues occurs. Accordingly, tyrosine nitration may
only be promoted in extracellular sites where nitric oxide fluxes
are high and superoxide and hypochlorite levels are not
sufficient to inhibit the reaction. However, the primary intention
with this study was to achieve PTMs which might cause a
conformational change. It is unlikely that the conditions used to
achieve this might occur in vivo even at sites undergoing
oxidative stress during prion disease. Moreover, as yet there is
no report of nitrated PrP having been detected in infected
material. However, it is still possible that a minor population of
modified protein might not have been detected. This might be
sufficient to allow propagation of conformational change even
though the majority population of PrPSc studied would not
contain any modification per se.
The kinetics of modified rPrP aggregation under the
conditions used in our studies was that of an apparent first
order reaction, dependent solely on the concentration of rPrP.
Fig. 7. Ability of modified rPrP to act as a template—using unlabelled rPrP. Unmodified rPrP was incubated in the absence (graphs a and c) or presence (graphs b and
d) of modified rPrP for 0 (graphs a and b) or 24 h (graphs c and d), as described in Methods. After incubation, modified rPrP was removed by centrifugation, as
described in Methods, and the supernatants of unmodified rPrP were treated with various concentrations of PK and analyzed by SDS-PAGE followed by Coomassie
staining, as described in Methods. Densitometry recorded relative amount of protein present at approximately 23 kDa(open square) and 12 kDa (open diamond).
Incubation in the presence of rPrP caused an increase in the amount of PK-resistant 12 kDa fragments. The results represent the mean of several independent samples
from the same batch of protein. Error bars depict one standard deviation.
Fig. 8. Ability of modified rPrP to act as a template—using labelled rPrP.
Modified rPrP can confer proteinase K resistance to unmodified rPrP, indicating
that the modified protein can act as a template to unmodified rPrP. 35S-labelled
rPrP produced by in vitro translation was incubated for 16 h at 37 °C with
unlabelled modified rPrP. Samples were analyzed by SDS-PAGE and autoradio-
graphy. Lane 1, unmodified rPrP produced by coupled in vitro transcription/
translation product of the ovine PrP gene; lane 2, PK digest of unmodified rPrP
translation product; lane 3, unmodified rPrP translation product templated with
modified rPrP; lane 4, PKdigest of templated unmodified rPrP translation product.
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Previous studies have suggested that a constant rate of aggregate
growth is indicative of a non-specific disordered process, as
might be expected with rapid aggregate formation that occurs in
a time scale of minutes rather than the more ordered process of
fibrillization which occurs in a time scale of hours [44].
Furthermore, it has been predicted that amyloid fibrillogenesis
of PrP is far more complex than disordered non-specific
aggregation but instead, consists of several stages of nucleation
and elongation each with their own distinct set of kinetic
parameters [44–46]. The physical nature of PrP aggregates that
occur in vivo during prion disease are either amorphous or
amyloid, such as scrapie-associated fibrils (SAFs) [14]. The
aggregates of modified rPrP reported here appeared to be a
mixture of physical forms comprising predominately amorphous
material inter-dispersed with fibrillar material. The observed
fibrillar material was of similar dimensions and helical
appearance to SAFs observed by electron microscopy following
sucrose gradient fractionation of scrapie-infected hamster brains
[47,48], but were unlike fibrils formed inmore recent work using
recombinant protein [49].
Modification of rPrP induced by the NO2
−/H2O2 system
resulted in significant structural changes within the protein as
evidenced by FT-IR spectroscopy. FT-IR spectra of unmodified
rPrP were characterised by a narrow amide I band centered at
1652 cm−1 indicative of α-helical structure. In contrast, spectra
of modified rPrP was characterised by a broader amide I band
centred at 1648 cm−1, in addition to a well-defined component
at 1621 cm−1, which is characteristic of β-sheet structure. These
data clearly indicated that the conformational change in rPrP
following oxidation/nitration was an increase in β-sheet content
with a simultaneous decrease in α-helix and random coil
structure.
A further property of rPrP exposed to NO2
−/H2O2 was the
acquisition of PK resistance, a feature characteristic of PrPSc.
Protease resistant aggregates of other proteins, such as
lysozyme and immunoglobulin light chains, that have been
exposed to high levels of oxidative stress reactants have also
been observed [50,51]. This is believed to occur as a
consequence of steric hindrance within the protein aggregate
with the resultant loss of enzyme access to the proteolytic
cleavage site. The PK resistance of modified rPrP observed in
our study could be due to a similar phenomenon. Protease-
resistance of the core of PrP has long been established as a key
characteristic by which PrPC and PrPSc are distinguished [52–
54]. Consequently, PK has been established as the proteolytic
enzyme used in both preparative and diagnostic detection of
PrPSc [47,55,56]. PK is an endolytic protease known to
hydrolyse the peptide bond on the carboxylic side of aromatic,
aliphatic or hydrophobic amino acid residues [57]. It is possible
therefore, that the acquisition of PK resistance by NO2
−/H2O2
exposed rPrP was a consequence not only of changes in protein
secondary structure but also was the result of chemical
modification of key amino acids within the protein molecule.
This view is supported by the observations that show that di-
tyrosine cross-linking, a chemical modification known to occur
under conditions of OS, renders proteins resistant to proteolytic
degradation [21]. In vivo, PK-resistant PrPSc is glycosylated
and is generally characterised by a PK-resistant core migrating
to between 27 and 30 kDa by SDS-PAGE [5]. Consequently
unglycosyated PrPSc is expected to have a protease-resistant
core of around 17 kDa [5]. The PK-resistant core evident in the
unglycosylated modified rPrP in the experiments reported here
was 12 kDa. This indicates that the our modifications of rPrP do
not appear to have resulted in a conformational form of PrP that
is completely analogous that found in vivo within TSE affected
individuals. However, recent reports of a sub-population of
PrPSc in sporadic CJD cases with a PK-resistant core of 12 kDa,
indicate that our protein may have a structure similar to this
protein. Interestingly, rPrP refolded into fibrils, analogous to
those shown to be infectious [7] has also been shown to have
limited PK-resistance and generates a PK-resistant core of
similar size [49].
In future work, we need to assess the effects of oxidative
stress reactants on glycosylated and membrane-bound/cellular
PrPc and to demonstrate their effect on cells in culture. This is
especially the case in the light of recent work by the Aguzzi
group [58] which shows that chronic inflammation can lead to
an expanded and unexpected distribution of prions. As chronic
inflammation is commonly associated with oxidative stress
conditions, our findings of their effects on the conformation of
recombinant prion protein may well reflect the reasons behind
this expanded distribution. With respect to PK-resistance, it
should be noted that parallel experiments on lysozyme also gave
rise to a PK-resistant core. This indicated that the effect of
modifying a protein and affecting its resistance to PK is not
specific to prion protein. However, as sequence similarity is a
prerequisite to templating ability [40] it is unlikely that modified
lysozyme would act as a template for conversion of unmodified
recombinant prion protein.
A key finding in our experiments was the observation that
modified rPrP could act as a template to induce PrPSc-like
characteristics in unmodified rPrP. In our study the templating
ability was assessed by the induction of both structural
modification and PK resistance as has been utilized in other
in vitro conversion assay systems [40,59]. The fact that the
modified rPrP aggregated and could be pelleted by centrifuga-
tion meant that this material could be separated from
unmodified rPrP to allow a comparison of the secondary
structures of the two forms of PrP. It should be noted that the FT-
IR spectrum of the unmodified protein prior to templating had a
broader alpha-helical peak than expected. This observed
increase in beta sheet secondary structure detected on FT-IR
analysis of stored unmodified rPrP as well as the increase in PK
resistance of the 12-kDa digestion products of stored unmodi-
fied rPrP (see below) would seem to reinforce observations of
others that spontaneous conformational changes might occur in
stored recombinant protein due to spontaneous PTMs such as
deamidation and/or oxidation [15]. Confirmation of this
possibility will require future mass spectroscopic analysis of
such stored protein samples. The FT-IR spectral analysis of
unmodified, templated rPrP that remained in the supernatant of
the templating reaction mixture gave a well-resolved β-sheet
band which was absent in the untemplated sample and
resembles the spectrum of the modified protein in Fig 3.
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In addition to templating structural changes, modified rPrP
was also capable of inducing PK-resistance in unmodified rPrP.
Results from the radiolabelled protein translation templating
experiment showed the presence of a 17-kDa PK-resistant PrP
core of unmodified rPrP following incubation with modified
rPrP whereas the digestion product was 12 kDa when
recombinant PrP was used. The difference in size between the
PK digestion products obtained in the two templating experi-
ments could have been due to a number of factors which need to
be resolved. The radiolabelled PrP translation product is
unglycosylated and before incubation in the presence of
modified rPrP is digested completely in the presence of PK.
Unglycosylated PrPSc is expected to yield a product size of
17 kDa on PK digestion [40] and therefore, we could claim that
as the radiolabelled translation product yields a 17-kDa product
after templating, this product is of the expected size. However,
the translation product was produced with the leader peptide in
place and it is possible that this may not have been removed by
the PK due to steric hindrance. This might account for the
increased size of this digestion product in comparison to that
obtained from the templating experiment using rPrP. Alterna-
tively, the leader peptide may have been removed and the 17-
kDa product could have resulted from the templating of an
alternative conformation from the modified rPrP template,
which was PK resistant. The 12-kDa digestion product which
resulted from the experiment usingmodified rPrP as the template
in the presence of excess unmodified rPrP is smaller than
expected and would tend to suggest that our modifications have
not produced a molecule entirely similar to PrPSc. Alternatively,
it could be speculated that this is an, as yet, unidentified
peculiarity of our rPrP. Collectively, our data support a view that
PTMswithin PrP can induce PrPSc-like characteristics within the
protein and that these characteristics can be templated onto
unmodified PrP. It is likely that other PTMs may induce PrPSc-
like qualities in PrP. Our own unpublished data has shown that
arginine to citrulline modifications of rPrP can also change the
secondary structure of PrP and produce a 12-kDa PK-resistant
core (Young et al., in preparation). Moreover, arginine to
citrulline modifications have been found in PrPSc [60]. In
addition, copper has been shown to induce the production of
oxo-histidine and/or aspartate in rPrP that subsequently results in
aggregation of the molecule [61]. It would seem pertinent to
analyze further those PTMs and their combinations. that are
capable of inducing both secondary structural changes and PK-
resistance in rPrP that more closely resemble PrPSc-like
characteristics displayed by disease-associated PrP found in
vivo during prion disease, for example a 17-kDa unglycosylated
PK-resistant core. Furthermore, identification of the biochem-
ical pathways responsible for the modification induced by
oxidative stress conditions on PrP may offer new targets for
therapeutic intervention in prion diseases.
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